Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 3,088 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 3,088 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $93,967.84. Following the sale, the chief financial officer now owns 129,211 shares of the company’s stock, valued at $3,931,890.73. The trade was a 2.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Friday, January 17th, Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total transaction of $51,830.80.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $30.76 on Friday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The firm has a market cap of $3.83 billion, a PE ratio of -15.15 and a beta of 0.94. The company’s 50 day moving average price is $31.95 and its two-hundred day moving average price is $33.25. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue was up 78.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.17) EPS. Equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Mizuho reduced their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Royal Bank of Canada reiterated a “sector perform” rating and set a $26.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday. Piper Sandler reduced their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a report on Wednesday, November 6th. Scotiabank lowered their price target on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 6th. Finally, Evercore ISI upgraded shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Large investors have recently bought and sold shares of the company. State of New Jersey Common Pension Fund D raised its position in Apellis Pharmaceuticals by 6.6% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock worth $1,735,000 after purchasing an additional 2,820 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Apellis Pharmaceuticals by 42.2% in the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after buying an additional 39,931 shares during the period. Amalgamated Bank raised its position in shares of Apellis Pharmaceuticals by 5.4% during the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after acquiring an additional 359 shares during the last quarter. Xponance Inc. lifted its stake in shares of Apellis Pharmaceuticals by 7.6% in the second quarter. Xponance Inc. now owns 13,773 shares of the company’s stock worth $528,000 after acquiring an additional 968 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in Apellis Pharmaceuticals in the second quarter valued at approximately $2,350,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).